Investor Presentaiton
Revised 2023 Guidance
US GAAP*
Total Revenues
Reported Rates
Total Revenues
Ex-FX
Revlimid
Gross Margin %
Non-GAAP*
October (Revised)
July (Prior)
October (Revised)
July (Prior)
Low-single digit decline
No Change
Low-single digit decline
No Change
Low-single digit decline
No Change
Low-single digit decline
No Change
-$5.5 billion
-$6.0 billion
-$5.5 billion
-$6.0 billion
~76%
No Change
-76%
No Change
Operating Expenses1
Low-single digit decline
No Change
Low-single digit decline
No Change
Tax Rate
Diluted EPS
ll Bristol Myers Squibb Q3 2023 Results
-16%
$3.72 - $4.02
~11%
$3.68 $3.83
~17.5%
$7.35 - $7.65
1. Operating Expenses = MS&A and R&D, excluding Acquired IPR&D and Amortization of acquired intangibles
*See "Forward-Looking Statements and Non-GAAP Financial Information"
~15.5%
$7.50 - $7.65
Not for Product Promotional Use
21View entire presentation